Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 44, Issue 11, 2003, Pages 1947-1950

  Shvidel, Lev ^a   Shtalrid, Mordechai ^a   Bairey, Osnat ^b   Rahimi Levene, Naomi ^c   Lugassy, Gilles ^d   Shpilberg, Ofer ^e   Polliack, Aaron ^f   Berrebi, Alain ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d BARZILAI MEDICAL CENTER   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

CLL; Elderly; Fludarabine; PR nodular

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ANTIBIOTIC AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 0242719927     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000110991     Document Type: Article

References (17)

1. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. and Schiffer, C.A. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", N. Engl. J. Med. 343, 1750-1757.
2. O'Brien, S., Kantarjian, H., Cortes, J., Beran, M., Koller, C., Giles, F.J., Lerner, S. and Keating, M. (2001) "Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia", J. Clin. Oncol. 19, 1414-1420.
3. Bosch, F., Perales, M., Cobo, F., Esteve, J., Rafel, M., Lopez-Guillermo, A., Ribera, J.M., Campo, E. and Montserrat, E. (1997) "Fludarabine, cyclophosphamide and mitoxantrone therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma", Blood 90s1, 530a.
4. Cheson, B.D. (1995) "Infectious and immunosuppressive complications of purine analog therapy", J. Clin. Oncol. 13, 2431-2448.
5. Keating, M.J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Childs, C.C., Freireich, E.J. and McCredie, K.B. (1991) "Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia", J. Clin. Oncol. 9, 44-49.
6. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. and Rai, K.R. (1996) "+National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood 87, 4990-4997.
7. Keating, M.J., Smith, T.L., Lerner, S., O'Brien, S., Robertson, L.E., Kantarjian, H. and Freireich, E.J. (2000) "Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia", Leuk. Lymphoma 37, 71-85.
8. Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. and Cheson, B.D. (1997) "Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report", J. Clin. Oncol. 15, 458-465.
9. Bosanquet, A.G. and Bosanquet, M.I. (2000) "Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia", Leukemia 14, 712-715.
10. Zinzani, L.P., Bendandi, M., Magagnoli, M., Albertini, P., Rondelli, D., Stefoni, V., Tani, M. and Tura, S. (2000) "Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia", Haematologica 85, 1135-1139.
11. Robak, T., Blasinska-Morawiec, M., Blonski, J.Z. and Dmoszynska, A. (1999) "2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia", Leuk. Lymphoma 34, 151-157.
12. Warrell, R.P., Jr and Berman, E. (1986) "Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity", J. Clin. Oncol. 4, 74-79.
13. Cheson, B.D., Vena, D.A., Foss, F.M. and Sorensen, J.M. (1994) "Neurotoxicity of purine analogs: a review", J. Clin. Oncol. 12, 2216-2228.
14. Gonzales, H., Bolgert, F., Camporo, P. and Leblond, V. (1999) "Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP)", Hematol. Cell Ther. 41, 183-186.
15. Di Raimondo, R., Giustolisi, R.R., Cacciola, E., O'Brien, S., Kantarjian, H., Robertson, L.B. and Keating, M.J. (1993) "Autoimmune hemolytic anemia in chronic lymphocytic leukemia treated by fludarabine", Leuk. Lymphoma 11, 63-69.
16. Marotta, G., Bigazzi, C., Lenoci, M., Tozzi, M., Bocchia, M. and Lauria, F. (2000) "Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy", Hematologica 85, 1268-1270.
17. Sudhoff, T., Arning, M. and Schneider, W. (1997) "Prophylactic strategies to meet infectious complications in fludarabine-treated CLL", Leukemia 11s2, s38.